The selection of nadulonimab by the Pancreatic Cancer Action Network for its adaptive clinical trial is a strong validation of the Stockholm-based firm's compound, which is also being evaluated for lung cancer.

Public Company Edition: Valuations have fallen enough in 2022 to lead some companies to wind down operations, but a recent uptick opened a window for a few offerings. Chinook raised $105m in a follow-on offering, while Flagship led a $79.2m registered direct offering for Evelo.

French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.

Biotech is developing engineered B-cell therapeutics for rare diseases and cancer. They should offer greater duration and better tolerability than T-cell therapies, the company claims.